Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 228

1.

Influence of Sustained Low-Efficiency Dialysis (SLED) treatment on Isavuconazole plasma levels in critically ill patients.

Lahmer T, Batres Baires G, Heilmaier M, Schmid RM, Sörgel F, Kinzig M, Huber W, Mayr U, Rasch S.

Antimicrob Agents Chemother. 2019 Aug 19. pii: AAC.01162-19. doi: 10.1128/AAC.01162-19. [Epub ahead of print]

PMID:
31427296
2.

A HILIC-MS/MS assay for the quantification of metformin and sitagliptin in human plasma and urine: A tool for studying drug transporter perturbation.

Scherf-Clavel O, Kinzig M, Stoffel MS, Fuhr U, Sörgel F.

J Pharm Biomed Anal. 2019 Oct 25;175:112754. doi: 10.1016/j.jpba.2019.07.002. Epub 2019 Jul 3.

PMID:
31336285
3.

Quantification of adefovir and pitavastatin in human plasma and urine by LC-MS/MS: A useful tool for drug-drug interaction studies.

Scherf-Clavel O, Kinzig M, Stoffel MS, Fuhr U, Sörgel F.

J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Sep 1;1125:121718. doi: 10.1016/j.jchromb.2019.121718. Epub 2019 Jul 16.

PMID:
31330406
4.

Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics.

Bulitta JB, Jiao Y, Landersdorfer CB, Sutaria DS, Tao X, Shin E, Höhl R, Holzgrabe U, Stephan U, Sörgel F.

Pharmaceutics. 2019 Jul 10;11(7). pii: E323. doi: 10.3390/pharmaceutics11070323.

5.

A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin.

Trueck C, Hsin CH, Scherf-Clavel O, Schaeffeler E, Lenssen R, Gazzaz M, Gersie M, Taubert M, Quasdorff M, Schwab M, Kinzig M, Sörgel F, Stoffel MS, Fuhr U.

Clin Pharmacol Ther. 2019 Jun 27. doi: 10.1002/cpt.1564. [Epub ahead of print]

PMID:
31247117
6.

Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding.

Shah NR, Bulitta JB, Kinzig M, Landersdorfer CB, Jiao Y, Sutaria DS, Tao X, Höhl R, Holzgrabe U, Kees F, Stephan U, Sörgel F.

Pharmaceutics. 2019 Jun 18;11(6). pii: E286. doi: 10.3390/pharmaceutics11060286.

7.

The contamination of valsartan and other sartans, part 1: New findings.

Sörgel F, Kinzig M, Abdel-Tawab M, Bidmon C, Schreiber A, Ermel S, Wohlfart J, Besa A, Scherf-Clavel O, Holzgrabe U.

J Pharm Biomed Anal. 2019 Aug 5;172:395-405. doi: 10.1016/j.jpba.2019.05.022. Epub 2019 May 11.

PMID:
31122801
8.

The contamination of valsartan and other sartans, Part 2: Untargeted screening reveals contamination with amides additionally to known nitrosamine impurities.

Scherf-Clavel O, Kinzig M, Besa A, Schreiber A, Bidmon C, Abdel-Tawab M, Wohlfart J, Sörgel F, Holzgrabe U.

J Pharm Biomed Anal. 2019 Aug 5;172:278-284. doi: 10.1016/j.jpba.2019.04.035. Epub 2019 Apr 16.

PMID:
31078064
9.

A long-time stability study of 50 drug substances representing common drug classes of pharmaceutical use.

Zilker M, Sörgel F, Holzgrabe U.

Drug Test Anal. 2019 Jul;11(7):1065-1075. doi: 10.1002/dta.2593. Epub 2019 May 2.

PMID:
30912309
10.

N-glycans of complex glycosylated biopharmaceuticals and their impact on protein clearance.

Higel F, Sandl T, Kao CY, Pechinger N, Sörgel F, Friess W, Wolschin F, Seidl A.

Eur J Pharm Biopharm. 2019 Jun;139:123-131. doi: 10.1016/j.ejpb.2019.03.018. Epub 2019 Mar 21.

11.

A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates.

Zilker M, Sörgel F, Holzgrabe U.

J Pharm Biomed Anal. 2019 Mar 20;166:222-235. doi: 10.1016/j.jpba.2019.01.016. Epub 2019 Jan 11.

PMID:
30660807
12.

Assessment of Pharmacokinetic Drug-Drug Interactions in Humans: In Vivo Probe Substrates for Drug Metabolism and Drug Transport Revisited.

Fuhr U, Hsin CH, Li X, Jabrane W, Sörgel F.

Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:507-536. doi: 10.1146/annurev-pharmtox-010818-021909. Epub 2018 Aug 29.

PMID:
30156973
13.

First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers.

Jiao Y, Kim TH, Tao X, Kinzig M, Landersdorfer CB, Drescher SK, Sutaria DS, Moya B, Holzgrabe U, Sörgel F, Bulitta JB.

Eur J Pharm Sci. 2018 Oct 15;123:416-428. doi: 10.1016/j.ejps.2018.07.054. Epub 2018 Aug 1.

PMID:
30076955
14.

Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects.

Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F.

Pharmacology. 2018;102(3-4):133-137. doi: 10.1159/000489999. Epub 2018 Jul 6.

PMID:
29982257
15.

Four Decades of β-Lactam Antibiotic Pharmacokinetics in Cystic Fibrosis.

Bulitta JB, Jiao Y, Drescher SK, Oliver A, Louie A, Moya B, Tao X, Wittau M, Tsuji BT, Zavascki AP, Shin BS, Drusano GL, Sörgel F, Landersdorfer CB.

Clin Pharmacokinet. 2019 Feb;58(2):143-156. doi: 10.1007/s40262-018-0678-x. Review.

PMID:
29936678
16.

Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal CYP3A: So What?

Gazzaz M, Kinzig M, Schaeffeler E, Jübner M, Hsin CH, Li X, Taubert M, Trueck C, Iltgen-Breburda J, Kraus D, Queckenberg C, Stoffel M, Schwab M, Sörgel F, Fuhr U.

Clin Pharmacol Ther. 2018 Dec;104(6):1249-1259. doi: 10.1002/cpt.1083. Epub 2018 May 10.

PMID:
29633238
17.

Azathioprine-induced reversible EBV-associated Hodgkin-like lymphoma after immunosuppressive therapy for autoimmune hepatitis
.

Munz M, Pretscher D, Wilhelm M, Holzgrabe U, Sörgel F, Birkmann J.

Int J Clin Pharmacol Ther. 2018 Mar;56)(3):142-147. doi: 10.5414/CP203106.

PMID:
29292695
18.

A stability-study of expired ampoules manufactured more than 40 years ago.

Zilker M, Sörgel F, Holzgrabe U.

J Pharm Biomed Anal. 2018 Feb 20;150:318-326. doi: 10.1016/j.jpba.2017.12.019. Epub 2017 Dec 13.

PMID:
29274583
19.

Severe Drug-Induced Liver Injury as an Adverse Drug Event of Antibiotics: A Case Report and Review of the Literature.

Munz M, Grummich H, Birkmann J, Wilhelm M, Holzgrabe U, Sörgel F.

Chemotherapy. 2017;62(6):367-373. doi: 10.1159/000480399. Epub 2017 Sep 22.

PMID:
28934748
20.

Quantification of Bisoprolol and Metoprolol in Simultaneous Human Serum and Cerebrospinal Fluid Samples.

Sigaroudi A, Kinzig M, Wahl O, Stelzer C, Schroeter M, Fuhr U, Holzgrabe U, Sörgel F.

Pharmacology. 2018;101(1-2):29-34. doi: 10.1159/000480091. Epub 2017 Sep 21.

21.

Population Modeling Integrating Pharmacokinetics, Pharmacodynamics, Pharmacogenetics, and Clinical Outcome in Patients With Sunitinib-Treated Cancer.

Diekstra MH, Fritsch A, Kanefendt F, Swen JJ, Moes D, Sörgel F, Kinzig M, Stelzer C, Schindele D, Gauler T, Hauser S, Houtsma D, Roessler M, Moritz B, Mross K, Bergmann L, Oosterwijk E, Kiemeney LA, Guchelaar HJ, Jaehde U.

CPT Pharmacometrics Syst Pharmacol. 2017 Sep;6(9):604-613. doi: 10.1002/psp4.12210. Epub 2017 Jul 13.

22.

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways.

Schiestl M, Zabransky M, Sörgel F.

Drug Des Devel Ther. 2017 May 16;11:1509-1515. doi: 10.2147/DDDT.S130318. eCollection 2017. Review.

23.

Environmental pollution with antimicrobial agents from bulk drug manufacturing industries in Hyderabad, South India, is associated with dissemination of extended-spectrum beta-lactamase and carbapenemase-producing pathogens.

Lübbert C, Baars C, Dayakar A, Lippmann N, Rodloff AC, Kinzig M, Sörgel F.

Infection. 2017 Aug;45(4):479-491. doi: 10.1007/s15010-017-1007-2. Epub 2017 Apr 26.

PMID:
28444620
24.

[Pharmacokinetics and pharmacodynamics of antibiotics in intensive care].

Sörgel F, Höhl R, Glaser R, Stelzer C, Munz M, Vormittag M, Kinzig M, Bulitta J, Landersdorfer C, Junger A, Christ M, Wilhelm M, Holzgrabe U.

Med Klin Intensivmed Notfmed. 2017 Feb;112(1):11-23. doi: 10.1007/s00063-016-0185-5. Epub 2016 Oct 24. Review. German.

PMID:
27778050
25.

Comparison of Pantoprazole Concentrations in Simultaneous Cerebrospinal Fluid and Serum Samples.

Sigaroudi A, Stelzer C, Braun T, Frechen S, Hüttner S, Schröter M, Kinzig M, Fuhr U, Holzgrabe U, Sörgel F.

Pharmacology. 2016;98(1-2):70-2. doi: 10.1159/000445720. Epub 2016 Apr 23.

PMID:
27104875
26.

Paul Ehrlich (1854-1915) and His Contributions to the Foundation and Birth of Translational Medicine.

Valent P, Groner B, Schumacher U, Superti-Furga G, Busslinger M, Kralovics R, Zielinski C, Penninger JM, Kerjaschki D, Stingl G, Smolen JS, Valenta R, Lassmann H, Kovar H, Jäger U, Kornek G, Müller M, Sörgel F.

J Innate Immun. 2016;8(2):111-20. doi: 10.1159/000443526. Epub 2016 Feb 5.

27.

Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.

Steffens M, Paul T, Hichert V, Scholl C, von Mallek D, Stelzer C, Sörgel F, Reiser B, Schumann C, Rüdiger S, Boeck S, Heinemann V, Kächele V, Seufferlein T, Stingl J.

Eur J Cancer. 2016 Mar;55:131-9. doi: 10.1016/j.ejca.2015.11.022. Epub 2016 Jan 25.

PMID:
26820683
28.

N-glycosylation heterogeneity and the influence on structure, function and pharmacokinetics of monoclonal antibodies and Fc fusion proteins.

Higel F, Seidl A, Sörgel F, Friess W.

Eur J Pharm Biopharm. 2016 Mar;100:94-100. doi: 10.1016/j.ejpb.2016.01.005. Epub 2016 Jan 13. Review.

29.

Adverse events during placebo vs. no drug administration--results of a randomised interventional trial in 160 volunteers.

Erbguth F, Hamacher-Erbguth A, Fuhr U, Sörgel F.

Eur J Clin Pharmacol. 2015 Nov;71(11):1403-5. doi: 10.1007/s00228-015-1900-5. Epub 2015 Aug 14. No abstract available.

PMID:
26268442
30.

N-glycan PK Profiling Using a High Sensitivity nanoLCMS Work-Flow with Heavy Stable Isotope Labeled Internal Standard and Application to a Preclinical Study of an IgG1 Biopharmaceutical.

Higel F, Seidl A, Demelbauer U, Viertlboeck-Schudy M, Koppenburg V, Kronthaler U, Sörgel F, Friess W.

Pharm Res. 2015 Nov;32(11):3649-59. doi: 10.1007/s11095-015-1724-0. Epub 2015 May 28.

31.

In memoriam: William A. Craig.

Theuretzbacher U, Ambrose PG, MacGowan AP, Andes DR, Sörgel F, Derendorf H, Mouton JW, Drusano GL, Tulkens PM, Dudley MN, Cars O, Nation RL.

Antimicrob Agents Chemother. 2015;59(6):2971. doi: 10.1128/AAC.00849-15. Epub 2015 Apr 20. No abstract available.

32.

Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics.

Sörgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M.

BioDrugs. 2015 Apr;29(2):123-31. doi: 10.1007/s40259-015-0124-7.

33.

Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa.

Rees VE, Bulitta JB, Nation RL, Tsuji BT, Sörgel F, Landersdorfer CB.

J Antimicrob Chemother. 2015 Mar;70(3):818-26. doi: 10.1093/jac/dku437. Epub 2014 Nov 6.

PMID:
25381167
34.

Small scale affinity purification and high sensitivity reversed phase nanoLC-MS N-glycan characterization of mAbs and fusion proteins.

Higel F, Seidl A, Demelbauer U, Sörgel F, Frieß W.

MAbs. 2014 Jul-Aug;6(4):894-903. doi: 10.4161/mabs.29263. Epub 2014 May 21.

35.

FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases--a CESAR phase II study including pharmacokinetic, biomarker, and imaging data.

Mross K, Scheulen M, Strumberg D, Kuhlmann J, Kanefendt F, Sörgel F, Jaehde U, Burkholder I, Moritz B, Büchert M.

Int J Clin Pharmacol Ther. 2014 Aug;52(8):642-52. doi: 10.5414/CP202109.

PMID:
24800922
36.

Evaluation of imipenem for prophylaxis and therapy of Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague.

Heine HS, Louie A, Adamovicz JJ, Amemiya K, Fast RL, Miller L, Opal SM, Palardy J, Parejo NA, Sörgel F, Kinzig-Schippers M, Drusano GL.

Antimicrob Agents Chemother. 2014 Jun;58(6):3276-84. doi: 10.1128/AAC.02420-14. Epub 2014 Mar 31.

37.

Challenges of surveying wastewater drug loads of small populations and generalizable aspects on optimizing monitoring design.

Ort C, Eppler JM, Scheidegger A, Rieckermann J, Kinzig M, Sörgel F.

Addiction. 2014 Mar;109(3):472-81. doi: 10.1111/add.12405. Epub 2013 Dec 10.

PMID:
24325468
38.

Pharmacokinetics of ertapenem in critically ill patients receiving continuous venovenous hemodialysis or hemodiafiltration.

Eyler RF, Vilay AM, Nader AM, Heung M, Pleva M, Sowinski KM, DePestel DD, Sörgel F, Kinzig M, Mueller BA.

Antimicrob Agents Chemother. 2014;58(3):1320-6. doi: 10.1128/AAC.02090-12. Epub 2013 Dec 9.

39.

Reversed-phase liquid-chromatographic mass spectrometric N-glycan analysis of biopharmaceuticals.

Higel F, Demelbauer U, Seidl A, Friess W, Sörgel F.

Anal Bioanal Chem. 2013 Mar;405(8):2481-93. doi: 10.1007/s00216-012-6690-3. Epub 2013 Jan 31.

40.

Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy.

Matzneller P, Krasniqi S, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, Zeitlinger M.

Antimicrob Agents Chemother. 2013 Apr;57(4):1736-42. doi: 10.1128/AAC.02011-12. Epub 2013 Jan 28.

41.

The therapeutic effect of tigecycline, unlike that of Ceftazidime, is not influenced by whether the Klebsiella pneumoniae strain produces extended-spectrum β-lactamases in experimental pneumonia in rats.

Goessens WH, Mouton JW, Ten Kate MT, Sörgel F, Kinzig M, Bakker-Woudenberg IA.

Antimicrob Agents Chemother. 2013 Jan;57(1):643-6. doi: 10.1128/AAC.01154-12. Epub 2012 Nov 5.

42.

Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile.

Landersdorfer CB, Bulitta JB, Kirkpatrick CM, Kinzig M, Holzgrabe U, Drusano GL, Stephan U, Sörgel F.

Antimicrob Agents Chemother. 2012 Nov;56(11):5715-23. doi: 10.1128/AAC.00937-12. Epub 2012 Aug 20.

43.

Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid.

Djukic M, Munz M, Sörgel F, Holzgrabe U, Eiffert H, Nau R.

Antimicrob Agents Chemother. 2012 Feb;56(2):979-88. doi: 10.1128/AAC.00437-11. Epub 2011 Nov 21.

44.

Blood, tissue, and intracellular concentrations of erythromycin and its metabolite anhydroerythromycin during and after therapy.

Krasniqi S, Matzneller P, Kinzig M, Sörgel F, Hüttner S, Lackner E, Müller M, Zeitlinger M.

Antimicrob Agents Chemother. 2012 Feb;56(2):1059-64. doi: 10.1128/AAC.05490-11. Epub 2011 Nov 14.

45.

Population pharmacokinetics and penetration into prostatic, seminal, and vaginal fluid for ciprofloxacin, levofloxacin, and their combination.

Bulitta JB, Kinzig M, Naber CK, Wagenlehner FM, Sauber C, Landersdorfer CB, Sörgel F, Naber KG.

Chemotherapy. 2011;57(5):402-16. doi: 10.1159/000329520. Epub 2011 Oct 18.

PMID:
22024700
46.

An LC-MS/MS procedure for the quantification of naproxen in human plasma: development, validation, comparison with other methods, and application to a pharmacokinetic study.

Elsinghorst PW, Kinzig M, Rodamer M, Holzgrabe U, Sörgel F.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jun 1;879(19):1686-96. doi: 10.1016/j.jchromb.2011.04.012. Epub 2011 Apr 20.

PMID:
21536505
47.

Comparable population pharmacokinetics and pharmacodynamic breakpoints of cefpirome in cystic fibrosis patients and healthy volunteers.

Bulitta JB, Kinzig M, Landersdorfer CB, Holzgrabe U, Stephan U, Sörgel F.

Antimicrob Agents Chemother. 2011 Jun;55(6):2927-36. doi: 10.1128/AAC.01484-10. Epub 2011 Mar 14.

48.

Development and validation of a liquid chromatography/tandem mass spectrometry procedure for the quantification of sunitinib (SU11248) and its active metabolite, N-desethyl sunitinib (SU12662), in human plasma: application to an explorative study.

Rodamer M, Elsinghorst PW, Kinzig M, Gütschow M, Sörgel F.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Apr 1;879(11-12):695-706. doi: 10.1016/j.jchromb.2011.02.006. Epub 2011 Feb 28.

PMID:
21367676
49.

Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia.

Lodise TP, Sorgel F, Melnick D, Mason B, Kinzig M, Drusano GL.

Antimicrob Agents Chemother. 2011 Apr;55(4):1606-10. doi: 10.1128/AAC.01330-10. Epub 2011 Feb 7.

50.

Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients.

Kanefendt F, Lindauer A, Kinzig M, Strumberg D, Scheulen ME, Mross K, Fischer R, Moritz B, Sörgel F, Jaehde U.

Int J Clin Pharmacol Ther. 2011 Jan;49(1):88-90. No abstract available.

PMID:
21176741

Supplemental Content

Loading ...
Support Center